Literature DB >> 27035640

TBX5 loss-of-function mutation contributes to atrial fibrillation and atypical Holt-Oram syndrome.

Dong-Feng Guo1, Ruo-Gu Li2, Fang Yuan2, Hong-Yu Shi2, Xu-Min Hou2, Xin-Kai Qu2, Ying-Jia Xu2, Min Zhang2, Xu Liu2, Jin-Qi Jiang3, Yi-Qing Yang2, Xing-Biao Qiu2.   

Abstract

Previous genome-wide association studies have demonstrated that single nucleotide polymorphisms in T‑box (TBX)5 are associated with increased susceptibility to atrial fibrillation (AF), and a recent study has causally linked a TBX5 mutation to atypical Holt-Oram syndrome and paroxysmal AF. However, the prevalence and spectrum of TBX5 mutations in patients with AF remain to be elucidated. In the present study, a cohort of 190 unrelated patients with idiopathic AF were prospectively recruited, with 400 unrelated healthy individuals recruited as controls. The coding exons and flanking introns of the TBX5 gene were sequenced in the participants. The functional characteristics of the mutant TBX5 were delineated in contrast with its wild‑type counterpart using a dual‑luciferase reporter assay system. As a result, a novel heterozygous TBX5 mutation, p.P132S, was identified in an index patient with AF, with a mutational prevalence of ~0.53%. Genetic analysis of the proband's family showed that the mutation co‑segregated with AF, and was transmitted in an autosomal dominant pattern. The missense mutation was absent in the 800 control chromosomes, and the altered amino acid was completely evolutionarily conserved across species. Functional analyses revealed that the mutant TBX5 had significantly reduced transcriptional activity. Furthermore, the mutation markedly decreased the synergistic activation between TBX5 and NK2 homeobox 5, another transcription factor which has been causatively linked to AF. The present study was the first, to the best of our knowledge, to report on the association between a TBX5 loss‑of‑function mutation and increased susceptibility to AF. These results provide novel insight into the molecular mechanism underpinning AF, and have potential implications in the development of novel prophylactic and therapeutic strategies for AF, the most common form of sustained cardiac arrhythmia.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27035640     DOI: 10.3892/mmr.2016.5043

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  11 in total

1.  ISL1 loss-of-function mutation contributes to congenital heart defects.

Authors:  Lan Ma; Juan Wang; Li Li; Qi Qiao; Ruo-Min Di; Xiu-Mei Li; Ying-Jia Xu; Min Zhang; Ruo-Gu Li; Xing-Biao Qiu; Xun Li; Yi-Qing Yang
Journal:  Heart Vessels       Date:  2018-11-02       Impact factor: 2.037

2.  Afterdepolarizations and abnormal calcium handling in atrial myocytes with modulated SERCA uptake: a sensitivity analysis of calcium handling channels.

Authors:  Andy C Y Lo; Jieyun Bai; Patrick A Gladding; Vadim V Fedorov; Jichao Zhao
Journal:  Philos Trans A Math Phys Eng Sci       Date:  2020-05-25       Impact factor: 4.226

Review 3.  Interplay between cardiac transcription factors and non-coding RNAs in predisposing to atrial fibrillation.

Authors:  Alexander T Mikhailov; Mario Torrado
Journal:  J Mol Med (Berl)       Date:  2018-05-12       Impact factor: 4.599

4.  A Novel MEF2C Loss-of-Function Mutation Associated with Congenital Double Outlet Right Ventricle.

Authors:  Cai-Xia Lu; Wei Wang; Qian Wang; Xing-Yuan Liu; Yi-Qing Yang
Journal:  Pediatr Cardiol       Date:  2018-02-21       Impact factor: 1.655

Review 5.  The Atrium in Atrial Fibrillation - A Clinical Review on How to Manage Atrial Fibrotic Substrates.

Authors:  Pedro Silva Cunha; Sérgio Laranjo; Jordi Heijman; Mário Martins Oliveira
Journal:  Front Cardiovasc Med       Date:  2022-07-04

Review 6.  Genetic and non-genetic risk factors associated with atrial fibrillation.

Authors:  Lindsay J Young; Steve Antwi-Boasiako; Joel Ferrall; Loren E Wold; Peter J Mohler; Mona El Refaey
Journal:  Life Sci       Date:  2022-04-03       Impact factor: 6.780

7.  TBX5 variant with the novel phenotype of mixed‑type total anomalous pulmonary venous return in Holt‑Oram Syndrome and variable intrafamilial heart defects.

Authors:  Bilal Azab; Dunia Aburizeg; Weizhen Ji; Lauren Jeffries; Nooredeen Jamal Isbeih; Amal Saleh Al-Akily; Hashim Mohammad; Yousef Abu Osba; Mohammad A Shahin; Zain Dardas; Ma'mon M Hatmal; Iyad Al-Ammouri; Saquib Lakhani
Journal:  Mol Med Rep       Date:  2022-05-06       Impact factor: 3.423

Review 8.  Atrial Fibrillation: Focus on Myocardial Connexins and Gap Junctions.

Authors:  Yu-Han Guo; Yi-Qing Yang
Journal:  Biology (Basel)       Date:  2022-03-23

9.  A novel de novo TBX5 mutation in a patient with Holt-Oram syndrome leading to a dramatically reduced biological function.

Authors:  Martina Dreßen; Harald Lahm; Armin Lahm; Klaudia Wolf; Stefanie Doppler; Marcus-André Deutsch; Julie Cleuziou; Jelena Pabst von Ohain; Patric Schön; Peter Ewert; Ivan Malcic; Rüdiger Lange; Markus Krane
Journal:  Mol Genet Genomic Med       Date:  2016-07-14       Impact factor: 2.183

10.  TBX5 R264K acts as a modifier to develop dilated cardiomyopathy in mice independently of T-box pathway.

Authors:  Nariaki Miyao; Yukiko Hata; Hironori Izumi; Ryo Nagaoka; Yuko Oku; Ichiro Takasaki; Taisuke Ishikawa; Shinya Takarada; Mako Okabe; Hideyuki Nakaoka; Keijiro Ibuki; Sayaka Ozawa; Tomoyuki Yoshida; Hideyuki Hasegawa; Naomasa Makita; Naoki Nishida; Hisashi Mori; Fukiko Ichida; Keiichi Hirono
Journal:  PLoS One       Date:  2020-04-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.